Wednesday, June 12, 2024 3:53:03 PM
Hosai, check under Section 2.4.1.1: Requesting the appointment of CHMP/PRAC/CAT rapporteurs/(co-)rapporteurs and their assessment teams
"We advise applicants to notify the EMA of their intent to submit and request assignment of (co-) rapporteurs seven months prior to the intended submission date. Although applicants may submit the letter of intent earlier than seven months prior to the intended submission date, the (co-)rapporteurs appointment procedure will not be initiated prior to that date."
On March 4th at the TD Cowen Conference Missling said that they were in the rapporteur application process and were awaiting notification of rapporteurs. Submission deadlines for the rapporteur appointment requests in 2024 prior to 4 March were on 10 January and next on 7 February. (There was no submission date in December of 2023.) If Anavex hit the January filing deadline, appointments were to be made by 19-22 February, so the notification was more than a week overdue. That, I suppose, was possible, but more conservatively I would presume that they filed by the February date. Worst case, if they filed on that date, the projected MAA submission would have been 7 September. Yes, it could happen earlier in the quarter if they submitted by 10 January and the EMA was late in responding. We do know, however that they didn't file for rapporteur appointment in November or December of 2023, so a Q2 2024 MAA submission was/is out of the question. Looks to me like mid/late August or the first week of September. Hope all this was reasonably clear and helpful.
"We advise applicants to notify the EMA of their intent to submit and request assignment of (co-) rapporteurs seven months prior to the intended submission date. Although applicants may submit the letter of intent earlier than seven months prior to the intended submission date, the (co-)rapporteurs appointment procedure will not be initiated prior to that date."
On March 4th at the TD Cowen Conference Missling said that they were in the rapporteur application process and were awaiting notification of rapporteurs. Submission deadlines for the rapporteur appointment requests in 2024 prior to 4 March were on 10 January and next on 7 February. (There was no submission date in December of 2023.) If Anavex hit the January filing deadline, appointments were to be made by 19-22 February, so the notification was more than a week overdue. That, I suppose, was possible, but more conservatively I would presume that they filed by the February date. Worst case, if they filed on that date, the projected MAA submission would have been 7 September. Yes, it could happen earlier in the quarter if they submitted by 10 January and the EMA was late in responding. We do know, however that they didn't file for rapporteur appointment in November or December of 2023, so a Q2 2024 MAA submission was/is out of the question. Looks to me like mid/late August or the first week of September. Hope all this was reasonably clear and helpful.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
